We are a provider of road maintenance, snow removal and sanitation equipment and related services in China. We specialize in the development, manufacture and direct sales of customized and standard road maintenance, snow removal and sanitation equipment with the goal of providing integrated solutions to our existing and potential customers for their needs in the […]

  We are a leading provider of aesthetic medical services in China. Leveraging over 20 years of clinical experience, we provide one-stop aesthetic service offerings that includes (i) surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation and liposuction, (ii) non-surgical aesthetic treatments which comprise minimally invasive treatments and energy-based treatments such as laser, ultrasound and ultraviolet […]

  Youdao makes learning happen. For over a decade, Youdao has developed and used technologies to provide learning content, applications and solutions to users of all ages. We’re the leading intelligent learning company in China with over 100.0 million average total MAUs in the first half of 2019. Starting from online knowledge tools, we currently offer […]

  We are a development-stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors. Our proprietary Therapeutic Vector Evolution platform enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the […]

  We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, […]

  We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Our lead CAAR T cell […]

We are a prominent brand and a pioneering platform dedicated to serving New Economy participants in China. New Economy is rapidly transforming businesses through cutting-edge technology and innovative business models. New Economy covers a wide and expanding spectrum of industries, including the Internet, hardware and software technologies, consumer and retail and finance industries. It has […]

(MingZhu was priced on 10/21/20 at $4 on 3 million shares, on its SEC-filed terms, and opened 10/21/20 at $4.40; it closed at $4.25 on its first day.) From the prospectus: We are one of the fastest-growing 3A-grade trucking services providers in China with 18 years of experience in the transportation industry. We formed our […]

  We intend to focus on businesses in Latin America within sectors that are underrepresented on public exchanges, including but not limited to natural resources, industrial operations and financial services and technology sectors, and therefore represent the potential for valuation arbitrage between private M&A comparables and public valuations.

  We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. The most common class of genetic mutations are errors of a single base, known as point mutations. These point […]